iCRT14 can appropriately reduce DVL2 without affecting its phosphorylation, and also affect TCF-CTNNB1 interactions (45); ICG-001 antagonizes WNT/CTNNB1/TCF-mediated transcription and specifically binds to promoter binding protein (46); nitazoxanide (NTZ) can increase the citrullination and turnover of CTNNB1 in cancer cells (47). The gene discussed is DVL2; the disease is cancer.